The panel that updates federal Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV is accepting nominations for a new community representative

ACE TA Center webinars covering Medicare and Medicare-Medicaid dual eligibility for RWHAP clients.

New grant awards for the latest round of funding of research on HIV interventions under the Ending the HIV Epidemic Initiative have been announced.

A decade of impact: The ACE TA Center's milestones and what’s new.

Long-acting antiretroviral therapy (ART) with cabotegravir and rilpivirine was superior in suppressing HIV replication compared to daily oral ART in people who had been unable to maintain viral suppression through an oral daily regimen.